The recent FDA approval of Lilly’s Kisunla (donanemab) represents a significant win in Alzheimer’s drug development, a field that has seen a decades of false starts and fizzled hopes. This approval, along with that of lecanemab in 2023, could mark a turning point in AD treatment. Alzheimer’s disease is reaching epidemic proportions with an estimated…
Improving clinical trial ROI with medication adherence management
Study power is the holy grail of clinical trials, setting drug developers on the quickest path to market — but nonadherence causes costly detours. When participants do not take their medication as specified in the study protocol, it can result in underestimated drug efficacy, delay the approval of investigational products, and contribute to rising costs.…